A new EPIC report says data brokers, ad-tech surveillance, and ICE enforcement are among the factors leading to a "health privacy crisis" that is eroding trust and deterring people from seeking care. When immigration agents enter hospitals and private companies are allowed to buy and sell data that reveals who seeks medical care, patients retreat, treatment is delayed, and health outcomes worsen, according to a new report that describes a growing "health privacy crisis" in the United States driven by surveillance and weak law enforcement limits. The report, published by the Electronic Privacy Information Center (EPIC), attributes the problem to outdated privacy laws and rapidly expanding digital systems that allow health-related information to be tracked, analyzed, breached, and accessed by both private companies and government agencies. EPIC, a Washington-based nonprofit focused on privacy and civil liberties, based its findings on a review of federal and state laws, court rulings, agency policies, technical research, and documented case studies examining how health data is collected, shared, and used across government and commercial systems. "Unregulated digital technologies, mass surveillance, and weak privacy laws have created a health privacy crisis," the report says.

In the past decade a surge in the amount of electronic health record (EHR) data in the United States, attributed to a favorable policy environment created by the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009 and the 21st Century Cures Act of 2016. Clinical notes for patients' assessments, diagnoses, and treatments are captured in these EHRs in free-form text by physicians, who spend a considerable amount of time entering and editing them. Manually writing clinical notes takes a considerable amount of a doctor's valuable time, increasing the patient's waiting time and possibly delaying diagnoses. Large language models (LLMs) possess the ability to generate news articles that closely resemble human-written ones. We investigate the usage of Chain-of-Thought (CoT) prompt engineering to improve the LLM's response in clinical note generation. In our prompts, we use as input International Classification of Diseases (ICD) codes and basic patient information. We investigate a strategy that combines the traditional CoT with semantic search results to improve the quality of generated clinical notes. Additionally, we infuse a knowledge graph (KG) built from clinical ontology to further enrich the domain-specific knowledge of generated clinical notes. We test our prompting technique on six clinical cases from the CodiEsp test dataset using GPT-4 and our results show that it outperformed the clinical notes generated by standard one-shot prompts.

Drug recommendation (DR) systems aim to support healthcare professionals in selecting appropriate medications based on patients' medical conditions. State-of-the-art approaches utilize deep learning techniques for improving DR, but fall short in providing any insights on the derivation process of recommendations -- a critical limitation in such high-stake applications. We propose TraceDR, a novel DR system operating over a medical knowledge graph (MKG), which ensures access to large-scale and high-quality information. TraceDR simultaneously predicts drug recommendations and related evidence within a multi-task learning framework, enabling traceability of medication recommendations. For covering a more diverse set of diseases and drugs than existing works, we devise a framework for automatically constructing patient health records and release DrugRec, a new large-scale testbed for DR.

(Figure 2).

In clinical practice, physicians refrain from making decisions when patient information is insufficient. This behavior, known as abstention, is a critical safety mechanism preventing potentially harmful misdiagnoses. Recent investigations have reported the application of large language models (LLMs) in medical scenarios. However, existing LLMs struggle with the abstentions, frequently providing overconfident responses despite incomplete information. This limitation stems from conventional abstention methods relying solely on model self-assessments, which lack systematic strategies to identify knowledge boundaries with external medical evidences. To address this, we propose \textbf{KnowGuard}, a novel \textit{investigate-before-abstain} paradigm that integrates systematic knowledge graph exploration for clinical decision-making. Our approach consists of two key stages operating on a shared contextualized evidence pool: 1) an evidence discovery stage that systematically explores the medical knowledge space through graph expansion and direct retrieval, and 2) an evidence evaluation stage that ranks evidence using multiple factors to adapt exploration based on patient context and conversation history. This two-stage approach enables systematic knowledge graph exploration, allowing models to trace structured reasoning paths and recognize insufficient medical evidence. We evaluate our abstention approach using open-ended multi-round clinical benchmarks that mimic realistic diagnostic scenarios, assessing abstention quality through accuracy-efficiency trade-offs beyond existing closed-form evaluations. Experimental evidences clearly demonstrate that KnowGuard outperforms state-of-the-art abstention approaches, improving diagnostic accuracy by 3.93\% while reducing unnecessary interaction by 7.27 turns on average.

(Figure 2).

Interactive medical questioning is essential in real-world clinical consultations, where physicians must actively gather information from patients. While medical Large Language Models (LLMs) have shown impressive capabilities in static medical question answering, they predominantly operate under a reactive paradigm: generating answers directly without seeking additional information, which risks incorrect diagnoses in such interactive settings. To address this limitation, we propose ProMed, a reinforcement learning (RL) framework that transitions medical LLMs toward a proactive paradigm, equipping them with the ability to ask clinically valuable questions before decision-making. At the core of ProMed is the Shapley Information Gain (SIG) reward, which quantifies the clinical utility of each question by combining the amount of newly acquired information with its contextual importance, estimated via Shapley values. We integrate SIG into a two-stage training pipeline: (1) SIG-Guided Model Initialization uses Monte Carlo Tree Search (MCTS) to construct high-reward interaction trajectories to supervise the model, and (2) SIG-Augmented Policy Optimization, which integrates SIG and enhances RL with a novel SIG-guided Reward Distribution Mechanism that assigns higher rewards to informative questions for targeted optimization. Extensive experiments on two newly curated partial-information medical benchmarks demonstrate that ProMed significantly outperforms state-of-the-art methods by an average of 6.29% and delivers a 54.45% gain over the reactive paradigm, while also generalizing robustly to out-of-domain cases.

The rise of Large Language Models (LLMs) has enabled the development of specialized AI agents with domain-specific reasoning and interaction capabilities, particularly in healthcare. While recent frameworks simulate medical decision-making, they largely focus on single-turn tasks where a doctor agent receives full case information upfront -- diverging from the real-world diagnostic process, which is inherently uncertain, interactive, and iterative. In this paper, we introduce MIMIC-Patient, a structured dataset built from the MIMIC-III electronic health records (EHRs), designed to support dynamic, patient-level simulations. Building on this, we propose DynamiCare, a novel dynamic multi-agent framework that models clinical diagnosis as a multi-round, interactive loop, where a team of specialist agents iteratively queries the patient system, integrates new information, and dynamically adapts its composition and strategy. We demonstrate the feasibility and effectiveness of DynamiCare through extensive experiments, establishing the first benchmark for dynamic clinical decision-making with LLM-powered agents.

Cardiovascular disease (CVD) risk prediction models are essential for identifying high-risk individuals and guiding preventive actions. However, existing models struggle with the challenges of real-world clinical practice as they oversimplify patient profiles, rely on rigid input schemas, and are sensitive to distribution shifts. We developed AdaCVD, an adaptable CVD risk prediction framework built on large language models extensively fine-tuned on over half a million participants from the UK Biobank. In benchmark comparisons, AdaCVD surpasses established risk scores and standard machine learning approaches, achieving state-of-the-art performance. Crucially, for the first time, it addresses key clinical challenges across three dimensions: it flexibly incorporates comprehensive yet variable patient information; it seamlessly integrates both structured data and unstructured text; and it rapidly adapts to new patient populations using minimal additional data. In stratified analyses, it demonstrates robust performance across demographic, socioeconomic, and clinical subgroups, including underrepresented cohorts. AdaCVD offers a promising path toward more flexible, AI-driven clinical decision support tools suited to the realities of heterogeneous and dynamic healthcare environments.

The application of Large Language Models (LLMs) to various clinical applications has attracted growing research attention. However, real-world clinical decision-making differs significantly from the standardized, exam-style scenarios commonly used in current efforts. In this paper, we present the RiskAgent system to perform a broad range of medical risk predictions, covering over 387 risk scenarios across diverse complex diseases, e.g., cardiovascular disease and cancer. RiskAgent is designed to collaborate with hundreds of clinical decision tools, i.e., risk calculators and scoring systems that are supported by evidence-based medicine. To evaluate our method, we have built the first benchmark MedRisk specialized for risk prediction, including 12,352 questions spanning 154 diseases, 86 symptoms, 50 specialties, and 24 organ systems. The results show that our RiskAgent, with 8 billion model parameters, achieves 76.33% accuracy, outperforming the most recent commercial LLMs, o1, o3-mini, and GPT-4.5, and doubling the 38.39% accuracy of GPT-4o. On rare diseases, e.g., Idiopathic Pulmonary Fibrosis (IPF), RiskAgent outperforms o1 and GPT-4.5 by 27.27% and 45.46% accuracy, respectively. Finally, we further conduct a generalization evaluation on an external evidence-based diagnosis benchmark and show that our RiskAgent achieves the best results. These encouraging results demonstrate the great potential of our solution for diverse diagnosis domains. To improve the adaptability of our model in different scenarios, we have built and open-sourced a family of models ranging from 1 billion to 70 billion parameters. Our code, data, and models are all available at https://github.com/AI-in-Health/RiskAgent.